FDA Inspection 1263213 — Medpace, Inc.
The FDA completed an inspection of Medpace, Inc. on February 13, 2025 in Cincinnati, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 13, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cincinnati, OH (United States)